前收市價 | 10.95 |
開市 | 10.95 |
買盤 | 9.90 |
賣出價 | 10.40 |
拍板 | 125.00 |
到期日 | 2024-10-18 |
今日波幅 | 10.95 - 10.95 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 249 |
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma. Merck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockb